Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: Focus on critically ill patients

PharmacoEconomics

Volumn 29, Issue 8, 2011, Pages 705-717

  Reboli, Annette C ^a   Rotstein, Coleman ^b   Kett, Daniel H ^c   Maschio, Michael ^d   Cartier, Shannon ^d   Chambers, Richard ^e   Tarallo, Miriam ^e  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d i3 Global   (Canada)

^e PFIZER INC   (United States)

Author keywords

Anidulafungin; Antifungals; Candidaemia; Candidiasis; Cost analysis; Fluconazole

Indexed keywords

ANIDULAFUNGIN; FLUCONAZOLE;

ADULT; APACHE; ARTICLE; CANDIDEMIA; CATHETER REMOVAL; CRITICALLY ILL PATIENT; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDEMIA; CANDIDIASIS, INVASIVE; CLINICAL TRIALS, PHASE III AS TOPIC; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; DRUG COSTS; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 79960117342     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584810-000000000-00000     Document Type: Article

References (31)

1. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59 (4): 407-14 (Pubitemid 350186332)
2. Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003; 123 (5 Suppl.): S500-3
3. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis 1999; 29 (2): 239-44 (Pubitemid 29380177)
4. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20 (6): 1526-30
5. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial blood stream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39 (3): 309-17 (Pubitemid 39050477)
6. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J AntimicrobAgents 2008; 32 (2 Suppl.): S87-91
7. Chang A, Neofytos D, Horn D. Candidemia in the 21st century. Future Microbiol 2008; 3: 463-72
8. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37 (9): 1172-7 (Pubitemid 37372504)
9. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25 (7): 419-25 (Pubitemid 44078593)
10. Gagne JJ, Goldfarb NI. Candidemia in the in-patient setting: treatment options and economics. Expert Opin Pharmacother 2007; 8 (11): 1643-50 (Pubitemid 47296549)
11. Blot SI, Vandewoude KH, Hoste EA, et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113 (6): 480-5 (Pubitemid 35335800)
12. Olaechea PM, Palomar M, León-Gil C, et al., EPCAN Study Group. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23 (4): 323-30 (Pubitemid 38669943)
13. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41 (10): 1455-60 (Pubitemid 41579989)
14. Guery BP, Arendrup MC, Auzinger G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients, part I: epidemiology and diagnosis. Intensive Care Med 2009; 35 (1): 55-62
15. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356 (24): 2472-82 (Pubitemid 46919773)
16. Shorr AF, Kett DH, Sanchez S, et al. Outcomes in patients with invasive candidiasis treated with anidulafungin or fluconazole: comparison of response to treatment in ICU patients and/or patients with end-organ dysfunction. Crit Care Med 2007; 35 (12 Suppl.): A250
17. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (5): 503-35
18. Damle BD, Dowell JA, Walsky RL, et al. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 2009; 53 (3): 1149-56
19. Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47 (4): 461-70 (Pubitemid 46465954)
20. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27 (4): 781-8 (Pubitemid 29244335)
21. Wingard JR, Herbrecht R, Mauskopf J, et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007; 9 (3): 182-8 (Pubitemid 47231209)
22. Willke RJ, Glick HA, Polsky D, et al. Estimating countryspecific cost-effectiveness from multinational clinical trials. Health Econ 1998; 7 (6): 481-93 (Pubitemid 28479419)
23. Pharmacy Benefits Management Services. Drug pharmaceutical price [online]. Available from URL: . pbm.va.gov/DrugPharmaceuticalPrices.aspx [Accessed 2008 Dec 17]
24. Greene WH. Econometric analysis. 6th ed. Upper Saddle River (NJ): Prentice Hall, 2008
25. Dodd S, Bassi A, Bodger K, et al. A comparison of multivariable regression models to analyse cost data. J Eval Clin Pract 2006; 12 (1): 76-86 (Pubitemid 43219521)
26. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. Boca Raton (FL): Chapman & Hall/CRC, 1989
27. Rapp RP. Changing strategies for the management of invasive fungal infections. Pharmacotherapy 2004; 24 (2 Pt 2): 4-28S
28. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5 (1): 26-34 (Pubitemid 34160368)
29. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 2005; 366 (9495): 1435-42 (Pubitemid 41483809)
30. Wingard JR, Wood CA, Sullivan E, et al. Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther 2005; 27 (6): 960-9 (Pubitemid 41583535)
31. Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2006; 24 (6): 1743-53